Page 210«..1020..209210211212..220230..»

Category Archives: Psoriasis

sobre la psoriasis nada ES imposible para DIOS – Video

Posted: June 24, 2013 at 6:42 am


sobre la psoriasis nada ES imposible para DIOS
MINISTRANDO SOBRE LOS TEJIDOS DE LA PIEL Y EN LOS NERVIOS .

By: ROBERTO VARGAS

See more here:
sobre la psoriasis nada ES imposible para DIOS - Video

Posted in Psoriasis | Comments Off on sobre la psoriasis nada ES imposible para DIOS – Video

Moderate to Severe Plaque Psoriasis Research Study – Video

Posted: at 6:42 am


Moderate to Severe Plaque Psoriasis Research Study
Flaked Out? Frustrated by itchy, scaly patches of skin? Volunteer for a research study testing an investigational drug for moderate to severe psoriasis. http...

By: ResearchTrials

Continue reading here:
Moderate to Severe Plaque Psoriasis Research Study - Video

Posted in Psoriasis | Comments Off on Moderate to Severe Plaque Psoriasis Research Study – Video

Spotlight on National Psoriasis Foundation – Video

Posted: June 21, 2013 at 3:42 pm


Spotlight on National Psoriasis Foundation
Spotlight on National Psoriasis Foundation from Health Matters at Work. Like this? Watch the latest episode of Health Matters at Work on Blip! http://blip.tv...

By: healthcharities

Read more from the original source:
Spotlight on National Psoriasis Foundation - Video

Posted in Psoriasis | Comments Off on Spotlight on National Psoriasis Foundation – Video

Dermalex Treatment For Psoriasis

Posted: June 20, 2013 at 9:43 am


Dermalex Treatment For Psoriasis How it Affects the Skin - Dermalex
Dermalex treatment for psoriasis how it affects the skin. Dr Barbara Geusens of OmegaPharma discusses the effects of psoriasis of the skin. She explains ho...

By: DermalexChannel

Visit link:
Dermalex Treatment For Psoriasis

Posted in Psoriasis | Comments Off on Dermalex Treatment For Psoriasis

What are the Causes and Triggers of Psoriasis? – Dermalex – Video

Posted: at 9:43 am


What are the Causes and Triggers of Psoriasis? - Dermalex
What are the causes and triggers of psoriasis? - Dr Barbara Geusens from Omega Pharma discusses the characteristics, main causes and triggers of psoriasis an...

By: DermalexChannel

Originally posted here:
What are the Causes and Triggers of Psoriasis? - Dermalex - Video

Posted in Psoriasis | Comments Off on What are the Causes and Triggers of Psoriasis? – Dermalex – Video

Managing Your Psoriasis With Dermalex Psoriasis Cream – Dermalex – Video

Posted: at 9:43 am


Managing Your Psoriasis With Dermalex Psoriasis Cream - Dermalex
Managing your psoriasis with Dermalex psoriasis cream. Dr Barbara Geusens of OmegaPharma explains how Dermalex psoriasis cream works, who it is suitable for ...

By: DermalexChannel

Read this article:
Managing Your Psoriasis With Dermalex Psoriasis Cream - Dermalex - Video

Posted in Psoriasis | Comments Off on Managing Your Psoriasis With Dermalex Psoriasis Cream – Dermalex – Video

Oolong tea helps eczema, may help with psoriasis

Posted: at 9:43 am

Q: Your readers did it again! I've been drinking oolong tea for more than a month now, and the patches of psoriasis have disappeared, along with the flaking. I still have a couple of areas that need some ointment now and then, but overall I can wear shorts now without being embarrassed about my skin. (My skinny legs are another matter.) Thanks.

A: A study long ago in Japan found that oolong tea was effective in easing treatment-resistant eczema (Archives of Dermatology, January 2001), but we have found no studies of oolong tea for psoriasis.

Several visitors to our website have reported that drinking oolong tea eased their psoriasis. Others have noted that turmeric or cilantro also can be helpful.

Q: My husband has suffered with polyneuropathy for three years. After his doctors said there was no cure, we located a cure at our vitamin store and want to share it with others.

He takes 600 mg of alpha-lipoic acid (ALA) daily. We are elated with the results. We have a neighbor who also began taking it, and he, too, is much-improved.

A: A randomized, placebo-controlled study in Russia and Israel showed that 600 mg of ALA daily can greatly ease the symptoms of neuropathy (nerve pain) such as stabbing or burning pain, numbness and "pins and needles" (Diabetes Care, November 2006).

A recent article points out that ALA is one of the few treatments that has shown promise for diabetic polyneuropathy and calls for more research (Diabetes/ Metabolism Research and Reviews online, Feb. 5, 2013).

Another nonprescription approach to this problem is benfotiamine, a synthetic form of the B vitamin thiamine. We learned about it from Dr. Charles Beauchamp several years ago, and recently heard this from a reader: "I appreciate the suggestion of benfotiamine for my foot pain. Within a month it has totally cleared up, and I am ready to move to a maintenance regimen."

Q: My daughter had head lice several times when she was very young and her hair was long. The lice shampoos did not work at all.

Finally, we used mayonnaise in her hair. We applied it from the scalp to the ends and then wrapped her head with plastic wrap. We left it on for at least two hours while she watched her favorite DVD. When we washed her hair, you could see the lice rinsing out. We did this every three days for two weeks to make sure that they were all gone.

Read more from the original source:
Oolong tea helps eczema, may help with psoriasis

Posted in Psoriasis | Comments Off on Oolong tea helps eczema, may help with psoriasis

Caroline Duke no longer suffers from psoriasis I The McDougall Program – Video

Posted: June 17, 2013 at 7:47 pm


Caroline Duke no longer suffers from psoriasis I The McDougall Program
http://go2.sixpackshortcuts.com/SHPm What you do eat on an intermittent fasting diet plan is of less significance. It #39;s more about reducing your calorie inta...

By: diet309

See original here:
Caroline Duke no longer suffers from psoriasis I The McDougall Program - Video

Posted in Psoriasis | Comments Off on Caroline Duke no longer suffers from psoriasis I The McDougall Program – Video

Cellceutix Reports Kevetrin(TM) Dosing Increases and Prurisol(TM) Anti-Psoriasis Drug Stability Tests Underway

Posted: at 7:47 pm

BEVERLY, MA--(Marketwired - Jun 17, 2013) - Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the pharmaceutical tablets for the Company's clinical trial of Prurisol as a new drug candidate for the treatment of psoriasis have been formulated by Dr. Reddy's Laboratories and are currently undergoing stability testing.The stability testing is scheduled to be completed in about 45 days.

"We have been advised that stability testing began approximately two weeks ago and that the Prurisol tablets will be shipped to the clinical site in Europe before the end of the 60-day stability research in preparation for the commencement of the clinical trial," commented Leo Ehrlich, Chief Executive Officer at Cellceutix."We are enthusiastic about reaching another milestone for our company with the start of second clinical trial. We are very optimistic about the potential for Prurisol to reproduce the laboratory results showing the drug to effectively eliminate all signs of psoriasis."

Cellceutix also wishes to inform shareholders that it has recently conducted discussions with the University of Bologna regarding Kevetrin, the Company's novel anti-cancer drug currently in clinical trials at Dana-Farber Cancer Center and Beth Israel Deaconess Medical Center, for the planned clinical trial as a new drug candidate for Acute Myelogenous Leukemia, or AML.All regulatory submissions have been made and the hospital is awaiting Kevetrin reaching its Maximum Tolerated Dose in the trials at Dana-Farber before commencing their trial.

"We are taking a different approach to realize some of the benefits of conducting the clinical trials of both Prurisol and Kevetrin in Europe," said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix."It is a similar strategy that companies like Clovis Oncology employ to follow European protocol to target a broader, yet more specific, patient population.Through a promising pipeline and efficient development model, Clovis has built an impressive valuation.In our current trials at Dana-Farber, the protocol requires that we only treat Stage IV cancer patients, which presents its own set of unique challenges that can slow research.The good news is we are likely more than half way there in terms of the trial, and we are still increasing dosage. We are very pleased with the results to date especially considering the lower doses to date.With reference to the planned University of Bolognatrial, by utilizing protocol where a 'measurable stage' of the disease is not required for the patient, i.e., we are not limiting the trial to Stage IV patients, this should allow the trial to go much faster, and hopefully get that perfect 'poster.'"

About Kevetrin

As a completely new class of chemistry in medicine, Kevetrin has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

Further information on the clinical trial, titled "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at http://www.cellceutix.com.

Originally posted here:
Cellceutix Reports Kevetrin(TM) Dosing Increases and Prurisol(TM) Anti-Psoriasis Drug Stability Tests Underway

Posted in Psoriasis | Comments Off on Cellceutix Reports Kevetrin(TM) Dosing Increases and Prurisol(TM) Anti-Psoriasis Drug Stability Tests Underway

Shaving my Head for Psoriasis – Video

Posted: June 16, 2013 at 3:47 pm


Shaving my Head for Psoriasis

By: SYmedicine

Original post:
Shaving my Head for Psoriasis - Video

Posted in Psoriasis | Comments Off on Shaving my Head for Psoriasis – Video

Page 210«..1020..209210211212..220230..»